TipRanks on MSN
Clarity wins FDA backing for phase III trial of Cu-64 SARTATE in neuroendocrine tumours
Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an announcement. Clarity Pharmaceuticals has secured positive guidance from the US Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback